AbbVie Inc. ($ABBV) Stock Forecast: Down 1.7% Today

What is AbbVie Inc.?

AbbVie (ABBV) is a pharmaceutical company recognized for its achievements in oncology and aesthetics. Recently, the company's stock faced a notable downward trend in the market.

Why is AbbVie Inc. going down?

ABBV stock is down 1.7% on Jun 18, 2026 14:41

• Despite the positive developments like the approval of SKINVIVE by JUVÉDERM and successful Phase 3 trial outcomes for a venetoclax-based therapy for chronic lymphocytic leukemia, the market response to these advancements may have been negative. Potential doubts about the new products' commercial success could have influenced investor sentiment.
• The selling of ABBV shares by OSTERWEIS CAPITAL MANAGEMENT INC, a notable holder of AbbVie stocks, might have also impacted market outlook. These actions by the firm could suggest a lack of faith in AbbVie's future performance.
• The decline in AbbVie's stock value could also be linked to industry-wide shifts or broader economic factors affecting the pharmaceutical sector. These external influences could prompt investors to reassess their positions in pharmaceutical companies like AbbVie.

ABBV Price Chart

ABBV Technical Analysis

ABBV News

AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress

AbbVie (ABBV) recently received U.S. FDA approval for SKINVIVE by JUVÉDERM to reduce neck lines, expanding its medical aesthetics portfolio. Concurrently, the company reported positive Phase 3 clinical trial results for a venetoclax-based combination therapy for untreated chronic lymphocytic leukemia in less-fit patients. These developments highlight AbbVie's growth in both its oncology and aesthetics divisions, offering new options for patients and reinforcing the company's dual-engine strategy for investors.

https://finance.yahoo.com/healthcare/articles/abbvie-abbv-lands-skinvive-approval-111353011.html

TG Therapeutics Inc (TGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

TG Therapeutics Inc (TGTX) has an earnings forecast score of 7.56, ranking 99th out of 157 in the Pharmaceuticals industry. Analysts have an average price target of $49.00 for TGTX, with a majority recommending a "Buy" trend. The company's expected revenue for the next quarter is $228.10 million, and its EPS for the prior quarter was $0.17, while the next quarter is projected at $0.36.

https://www.tradingkey.com/markets/stocks/nasdaq-tgtx/earnings

OSTERWEIS CAPITAL MANAGEMENT INC's AbbVie Inc(ABBV) Holding History

This article details OSTERWEIS CAPITAL MANAGEMENT INC's historical holdings in AbbVie Inc (ABBV). As of March 31, 2026, the firm holds 107,478 shares valued at $23.38 million, representing 1.43% of its portfolio. The initial trade was in Q1 2014, and the firm has made 7 purchases and 16 sales of ABBV, with an estimated gain of $554,597.09 on current holdings.

https://www.gurufocus.com/guru-portfolio/OSTERWEIS%20CAPITAL%20MANAGEMENT%20INC/ABBV

Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Puma Biotechnology Inc (PBYI) currently holds an earnings forecast score of 6.00, placing it 132nd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for PBYI, with an expected revenue of $53.00 million for the next quarter. The consensus analyst rating based on one analyst is "Hold."

https://www.tradingkey.com/markets/stocks/nasdaq-pbyi/earnings

Regeneron Pharmaceuticals Inc (REGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Regeneron Pharmaceuticals Inc (REGN) currently holds an earnings forecast score of 7.81, placing it 90th out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $767.00 for REGN, with a high of $1057.00 and a low of $627.00, and predominantly recommend a "Buy" trend. The company's expected revenue for the next quarter is $3.83 billion, with an anticipated EPS of $10.85, following a reported EPS of $8.19 in the previous quarter against an expectation of $6.99.

https://www.tradingkey.com/markets/stocks/nasdaq-regn/earnings

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

AbbVie Inc. Price History

29.03.2026 - ABBV Stock was up 3.2%

• AbbVie surpassed expectations for the first quarter of 2026, achieving net revenues of $15.002 billion, representing a 12.4% increase. The growth was mainly credited to the success of newer immunology medications like Skyrizi and Rinvoq, which offset the sales decline of Humira due to patent expiration.
• The company revised its full-year 2026 adjusted EPS guidance upwards, indicating confidence in its pipeline progress and core business. This optimistic outlook was reinforced by substantial growth in the neuroscience portfolio, notably with Botox Therapeutic surpassing $1 billion in quarterly sales for the first time.
• Investors reacted positively to AbbVie's impressive performance, being reassured by the company's adept handling of challenges like patent expiration and its ability to capitalize on innovative products to propel growth.
• AbbVie's strategic emphasis on developing and launching new medications, along with its continual investments in manufacturing and pipeline advancements, positions the company strongly for ongoing success in the pharmaceutical sector.

18.02.2026 - ABBV Stock was down 5.2%

• ABBV stock saw a 5% drop post the FDA approval of J&J's Icotyde, a new oral plaque psoriasis treatment, creating direct competition with AbbVie's Skyrizi.
• Analysts predict a 23% increase in Skyrizi sales by FY2026, notwithstanding the competition, showcasing some strength in AbbVie's market position.
• The decrease in ABBV stock value can be linked to worries regarding Icotyde's impact on Skyrizi's market presence, compounded by ongoing challenges from Humira's loss of exclusivity and falling aesthetics segment sales.
• With Icotyde's approval as a convenient oral option with high effectiveness compared to injectables, it presents a significant challenge to AbbVie's dominance in the psoriasis treatment sector, leading to a pessimistic outlook on ABBV stock.

18.02.2026 - ABBV Stock was down 5.0%

• The current downward movement in ABBV stock may be linked to significant reductions in holdings by Wilmington Savings Fund Society FSB, offloading 26,080 shares in the third quarter, as well as insider selling of substantial stakes.
• Despite AbbVie surpassing quarterly expectations and offering robust FY2026 guidance, the selling activities by major institutions and insiders could have triggered investor apprehensions, contributing to the current bearish trend.
• Information regarding Johnson & Johnson's FDA approval for a new oral psoriasis pill, Icotyde, creating competition in the psoriasis market, might have also impacted investor confidence in AbbVie's future market share and revenue potential.

18.02.2026 - ABBV Stock was down 5.2%

• Wilmington Savings Fund Society FSB notably decreased its stake in AbbVie Inc., selling off a significant number of shares, which might reflect a lack of confidence in the company's future.
• Despite AbbVie's outperformance in the last quarter and positive guidance for FY2026, concerns raised by a business health analysis regarding sluggish sales growth and declining financial metrics might have driven the bearish movement.
• The high payout ratio of 293.22%, resulting from a quarterly dividend of $1.73 per share, may have added to investor worries, particularly as insiders in leadership positions were observed selling portions of their shares.
• Danske Bank A S's substantial investment in AbbVie Inc. stands in contrast, potentially indicating divergent views on the stock's performance and future prospects.

18.02.2026 - ABBV Stock was down 5.4%

• AbbVie's stock experienced a significant 4.60% decline on March 18, driven by various factors including:
• Intense competition: Approval of a new oral peptide for psoriasis poses a direct threat to AbbVie's Skyrizi, impacting investor sentiment negatively.
• Biosimilar competition: Ongoing pressure from biosimilar competition for its blockbuster drug Humira continues to weigh on AbbVie's stock performance.
• Weakness in aesthetics business: Challenges in AbbVie's aesthetics business segment also contributed to the bearish movement of the stock.
• Despite some positive developments in AbbVie's pipeline, the combination of these factors led to a correction and weakening trend momentum in the stock price.
• The approval of a new drug by the FDA and its potential as a blockbuster drug with significant sales projections added further pressure on AbbVie's stock, highlighting the competitive landscape in the pharmaceutical industry.

05.00.2026 - ABBV Stock was down 2.6%

• Today's bearish movement in AbbVie's stock price can be attributed to several factors:
• Despite strong Q3 earnings and dividend increases, the reduction in holdings by institutional investors like Railway Pension Investments Ltd and Commonwealth Equity Services LLC may have signaled concerns about the company's future growth prospects.
• The $100 million upfront investment in the trispecific lung cancer drug ZG006, while positioning AbbVie to challenge competitors like Amgen, might have raised investor worries about the high costs and risks associated with drug development.
• The upcoming presentation at the J.P. Morgan Healthcare Conference could have led to profit-taking by some traders who may have been expecting more significant announcements or guidance from the management.
• The overall market sentiment towards pharmaceutical companies and healthcare stocks today might have also played a role in the bearish movement of AbbVie's stock, as investors may be rotating their portfolios based on sector performance and economic outlook.

04.01.2026 - ABBV Stock was down 8.6%

• AbbVie surpassed analyst estimates with its financial performance in Q4 2025, including strong revenue figures and a notable showing by Humira.
• Despite the optimistic earnings report and an increased profit forecast for 2026, the stock saw a minor decline, potentially influenced by investors taking profits following recent positive developments.
• Market response indicates that notwithstanding the company's positive outlook and solid performance, investors may have held elevated expectations or concerns regarding the future earnings impact of Humira's patent expiration.
• The slight drop in the stock price might also be linked to general market conditions or specific challenges within the pharmaceutical sector affecting investor sentiment.

18.05.2026 - ABBV Stock was down 1.7%

• Despite the positive developments like the approval of SKINVIVE by JUVÉDERM and successful Phase 3 trial outcomes for a venetoclax-based therapy for chronic lymphocytic leukemia, the market response to these advancements may have been negative. Potential doubts about the new products' commercial success could have influenced investor sentiment.
• The selling of ABBV shares by OSTERWEIS CAPITAL MANAGEMENT INC, a notable holder of AbbVie stocks, might have also impacted market outlook. These actions by the firm could suggest a lack of faith in AbbVie's future performance.
• The decline in AbbVie's stock value could also be linked to industry-wide shifts or broader economic factors affecting the pharmaceutical sector. These external influences could prompt investors to reassess their positions in pharmaceutical companies like AbbVie.

30.03.2026 - ABBV Stock was up 7.8%

• The bullish movement in AbbVie's stock is linked to its philanthropic partnership with Allergan Aesthetics, demonstrating a dedication to social responsibility and community involvement.
• The price target increase by Goldman Sachs signifies confidence in AbbVie's growth potential, especially with successful products like Skyrizi and Rinvoq and promising pipeline updates.
• AbbVie's positive outlook might have been reinforced by a competitor's underperformance, showcasing AbbVie's strength within the pharmaceutical sector.
• In conclusion, AbbVie's strategic efforts, strong product performance, and favorable analyst evaluations appear to have influenced the upward trend in its stock price.

07.00.2026 - ABBV Stock was up 5.1%

• AbbVie's price target was increased to $240 by UBS, reflecting optimism about the company's performance.
• GuruFocus forecasts a possible downside for ABBV, indicating mixed perspectives on the stock.
• The positive outlook for AbbVie's growth potential and position in the pharmaceutical sector could be driving the bullish trend.
• The stock's upward momentum may be a response to the news of the raised price target, garnering favorable investor reactions.

08.00.2026 - ABBV Stock was down 5.3%

• AbbVie's stock decreased after lowering its Q4 and full-year 2025 guidance, receiving a downgrade from Wolfe Research, and refuting acquisition discussions with Revolution Medicines. These developments likely influenced the bearish movement.
• Xilio Therapeutics raised $35.8 million through warrant exercises and met a development milestone with AbbVie, providing positive news for Xilio amidst AbbVie's challenges, potentially shifting investor focus.
• AbbVie's denial regarding Revolution Medicines acquisition rumors, following a surge in Revolution's stock, contributed to market volatility and potentially impacted AbbVie's stock decline.
• Market sentiment towards pharmaceutical companies and their strategic decisions, exemplified by the varied news on AbbVie and Revolution Medicines, may have also influenced AbbVie's stock performance today.